The landscape of oncology is undergoing a fundamental transformation as pharmaceutical giants Merck & Co. and Moderna move toward the…
Read More
2026 PharmSci 360 adds tracks on research credibility and post-animal drug development
The American Association of Pharmaceutical Scientists (AAPS) has unveiled a transformative agenda for its 2026 PharmSci 360 conference, slated for…
Read More
Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice
The global landscape of immunology has been irrevocably altered by the COVID-19 pandemic, leaving behind a pervasive, population-wide archive of…
Read More
DEA targets synthetic kratom-related products mitragynine pseudoindoxyl, MGM-15, and MGM-16 for temporary controls in Schedule I
In a significant move to address the rising proliferation of potent, lab-engineered substances, the U.S. Drug Enforcement Administration (DEA) has…
Read More
After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice
The search for an effective prophylactic against Chemotherapy-Induced Peripheral Neuropathy (CIPN) has been one of the most frustrating chapters in…
Read More
Pharma commercial vendor selection still runs on word of mouth: A Harvard MBA student aims to change that with Rx Almanac.
For pharmaceutical companies navigating the complex transition from clinical research to commercial launch, the selection of service providers—ranging from distribution…
Read More
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
A new paradigm in therapeutic development is emerging as Remepy, a pioneering startup, successfully completed a Phase IIa clinical trial…
Read More
As cell therapies scale and CDMOs cut staff, process know-how is often getting lost in tech transfer
The biopharmaceutical industry is grappling with a profound challenge: the silent erosion of critical process knowledge, particularly "tacit knowledge," during…
Read More
What if psilocybin works about as well for depression as an SSRI?
The burgeoning optimism surrounding classic psychedelics as a transformative treatment for depression is beginning to face a crucial reality check.…
Read More
Diabetes to MASH: The Specimens Behind GLP-1’s Widening Roster
The therapeutic landscape for metabolic disorders, and increasingly, a spectrum of other complex diseases, is undergoing a profound transformation, largely…
Read More
